Several studies reported that COVID-19 patients with hypertension using ACE inhibitors/ARBs had a lower mortality rate, the risk of ICU admission, maximal viral load, the need for mechanical ventilation, and also decreased concentrations of high sensitivity C-reactive protein (hs-CRP), procalcitonin, and IL-6. Here, ACE is linked to COVID-19.